Sotatercept significantly improved the six-minute walk distance by a mean difference of 34.99 meters compared to placebo in patients with pulmonary arterial hypertension.
Meta-Analysis (n=429)
Does sotatercept improve six-minute walk distance, WHO functional class, and pulmonary vascular resistance in patients with pulmonary arterial hypertension on background therapy?
Sotatercept added to background therapy significantly improves exercise capacity, functional class, and pulmonary hemodynamics in patients with pulmonary arterial hypertension.
Effect estimate: MD 34.99 (95% CI 19.02-50.95)
p-value: p=< 0.0001
Pulmonary arterial hypertension (PAH) results from proliferative remodeling and narrowing of the pulmonary vasculature. Sotatercept is a first-in-class fusion protein that has recently garnered attention for showing improvements in patients with PAH. This meta-analysis of randomized controlled trials (RCTs) assesses the overall efficacy of Sotatercept in treating PAH. PubMed, Google Scholar, and Clinicaltrials.gov were searched using relevant keywords and MeSH terms. Studies were included if RCTs compared Sotatercept with placebo in patients with PAH. Our comprehensive literature search yielded 3,127 results, of which two RCTs with 429 patients were included in this meta-analysis. The patients were on background therapy for PAH. Results of the meta-analysis show that when compared with placebo, Sotatercept improved the six-minute walk distance (mean difference MD 34.99; 95% confidence interval CI 19.02-50.95; P < 0.0001), the World Health Organization (WHO) functional class (odds ratio OR 2.50; 95% CI 1.50-4.15; P = 0.0004), and pulmonary vascular resistance (PVR, MD -253.90; 95% CI -356.05 to -151.75; P < 0.00001). However, reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP, MD -1563.14; 95% CI -3271.93 to 145.65; P = 0.07) was not statistically significant in the Sotatercept group versus placebo. In conclusion, Sotatercept improves the six-minute walk distance, WHO functional class, and PVR in patients with PAH receiving background therapy. However, the effect on NT-proBNP levels was not statistically significant. More research is needed to assess the clinical relevance of these findings.
Uddin et al. (Mon,) conducted a meta-analysis in Pulmonary arterial hypertension (n=429). Sotatercept vs. Placebo was evaluated on Six-minute walk distance (MD 34.99, 95% CI 19.02-50.95, p=< 0.0001). Sotatercept significantly improved the six-minute walk distance by a mean difference of 34.99 meters compared to placebo in patients with pulmonary arterial hypertension.